← All trials
NCT05552495
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 23, 2022
- Primary completion
- Nov 27, 2022
- Completion date
- Dec 3, 2022
- First posted
- Sep 23, 2022
- Last posted
- Sep 23, 2022
- Enrollment
- 30
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chong Kun Dang PharmaceuticalLead sponsor
- Government of KoreaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.